KeyCorp Stock Drop Case Dismissed

A stock drop lawsuit has been dismissed, according to plaintiffs’ attorneys.

 

A press release from Stull, Stull & Brody says that on August 12, 2010, the United States District Court for the Northern District of Ohio, Eastern Division, granted KeyCorp’s motion to dismiss the ERISA class action complaint which was filed on behalf of certain participants who held KeyCorp common stock in their accounts in the Keycorp 401(k) Savings Plan.

The press release notes that the ERISA class action, Taylor v. KeyCorp, et al., No. 1:08-cv-01927, was brought on behalf of participants in the Plan whose Plan accounts held KeyCorp common stock at any time from December 31, 2006 to the present. According to the plaintiffs’ attorneys the case alleged that KeyCorp and other fiduciaries of the Plan breached their fiduciary duties by offering KeyCorp stock as an investment option under the Plan when KeyCorp stock was not a prudent investment for retirement savings accounts.

For more stories like this, sign up for the PLANADVISERdash daily newsletter.

The announcement noted that in dismissing the case, the Court ruled that neither of the plaintiffs who brought the suit had suffered injury from their holding of KeyCorp stock in their Plan accounts and, therefore, the plaintiffs lacked standing to sue. 

Law Firm Probes Drugmaker for 401(k) Missteps

A New York law firm is investigating whether fiduciaries of the GlaxoSmithKline 401(k) plan violated the Employee Retirement Income Security Act of 1974 (ERISA).

A news release from the Stull, Stull & Brody firm said it is looking into whether the company ran afoul of ERISA by not disclosing its true operating condition to participants and beneficiaries. Those disclosures included information about the safety of Avandia, a diabetes drug.

Other potential ERISA issues include offering GlaxoSmithKline ADRs as an investment option under the plans when it was not prudent to do so, and/or by allowing an imprudent overconcentration of company stock in the Company’s 401(k) plans.

Never miss a story — sign up for PLANADVISER newsletters to keep up on the latest retirement plan adviser news.

The drug has been under government scrutiny since 2007 into allegations it increases risks of heart problems.

More information about the probe can be obtained by calling 800-337-4983 or via e-mail at ssbny@aol.com.

«